Nanoplatforms For Cancer Theranostics

Research in nanoplatforms for cancer theranostics focuses on the development and application of nanoscale materials for the simultaneous diagnosis and treatment of cancer. This area explores the synthesis and characterization of novel nanoparticles, including liposomes, polymeric nanoparticles, and inorganic nanostructures. Investigations delve into how these nanoplatforms can be engineered to selectively target cancer cells, deliver therapeutic agents, and provide diagnostic information through imaging modalities. Key research activities include designing smart nanocarriers that respond to tumor microenvironments, optimizing drug loading and release kinetics, and evaluating the efficacy and safety of these systems in preclinical models. The ultimate goal is to create more effective and less toxic cancer therapies.

This work holds significant relevance for Arkansas. The state faces a considerable burden from cancer, making advancements in diagnosis and treatment a public health priority. Developing innovative theranostic approaches can lead to improved patient outcomes and potentially reduce healthcare costs. Furthermore, the research contributes to the growth of Arkansas's biotechnology and advanced materials sectors, fostering economic development through the creation of new technologies and intellectual property. Expertise in nanotechnology can also support existing industries in the state that utilize advanced materials.

This interdisciplinary field draws upon expertise in materials science, chemistry, biology, pharmacology, and medicine. The research is advanced by faculty and students across multiple Arkansas institutions, fostering collaboration in areas such as nanoparticle synthesis, cancer biology, drug delivery mechanisms, and biomedical imaging. Connections also extend to related fields including semiconductor materials, tissue engineering, and neuroscience.